Trial Profile
Prospective observational study on anti-CCP antibody titer and clinical effect of abatacept (orencia) on patients with rheumatoid arthritis -A pilot study-
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 31 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 23 Apr 2014 New trial record